Filing Flows

Filing Flows › Companies › Aurinia Pharmaceuticals › Cash flow

Aurinia Pharmaceuticals cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$46.4M in Q3 2026 · $177M over twelve months

Operating cash flow$46.4M
Free cash flow+$46.4M
Cash / net income1.5×

Analysis

In Q3 2026, Aurinia Pharmaceuticals generated $46.4M of operating cash flow. That is $1.9M more than in Q3 2025 ($44.4M).

Over the twelve months to Sep 30, 2026, operating cash flow was $177M; the largest uses were other investing ($149M), buybacks ($74.9M), taxes on employees’ shares ($34.0M); besides operations, cash came from shares issued ($71.9M); the cash balance fell by $27.0M.

Operating cash flow was $46.4M against net income of $31.7M — 1.5× profit, cash ran ahead of reported earnings. The largest differences: deferred taxes +$8.3M, receivables −$6.3M, stock-based pay +$6.1M.

Free cash flow

Aurinia Pharmaceuticals: free cash flow by quarterAurinia Pharmaceuticals: free cash flow by quarter$30.1MQ4 2024$1.3MQ1 2025$44.2MQ2 2025$44.4MQ3 2025$45.7MQ4 2025$32.6MQ1 2026$52.6MQ2 2026$46.4MQ3 2026
Operating cash flow less capital spending.
Aurinia Pharmaceuticals: operating cash flow against capital spendingAurinia Pharmaceuticals: operating cash flow against capital spendingOperating cash flowCapital spending$30.1M$0Q4 2024$1.3M$0Q1 2025$44.2M$0Q2 2025$44.4M$0Q3 2025$45.7M$0Q4 2025$32.6M$0Q1 2026$52.6M$0Q2 2026$46.4M$0Q3 2026
Latest (Q3 2026): Operating cash flow $46.4M, Capital spending $0.

Capital allocation, year by year

Aurinia Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearAurinia Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedBuybacksFY2021: Operating cash flow −$158MFY2021: Shares issued $221M$221MFY2021FY2022: Operating cash flow −$79.5MFY2022: Shares issued $3.5M$3.5MFY2022FY2023: Operating cash flow −$33.5MFY2023: Net borrowing −$10.0MFY2023: Shares issued $7.2M$7.2MFY2023FY2024: Operating cash flow $44.4MFY2024: Net borrowing −$12.0MFY2024: Shares issued $9.3MFY2024: Buybacks −$40.2M$53.7MFY2024FY2025: Operating cash flow $136MFY2025: Net borrowing −$13.1MFY2025: Shares issued $14.9MFY2025: Buybacks −$98.2M$151MFY2025
Over these 5 years operating cash flow totalled −$90.6M; the largest uses were operating cash flow ($271M) and buybacks ($138M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$45.8M
Debtnone
Net cash$45.8M

Aurinia Pharmaceuticals funds itself: free cash flow was $177M over the last twelve months, with $45.8M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

Aurinia Pharmaceuticals: sources (+) and uses (−) of cash, Q3 2026Aurinia Pharmaceuticals: sources (+) and uses (−) of cash, Q3 2026Other investing−$176MCash drawn (+) / kept (−)$134MOperating cash flow$46.4MShares issued$10.4MTaxes on employees’ shares−$7.2MNet borrowing (+) / repaid (−)−$3.8MOther financing−$3.7M
Aurinia Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 2026Aurinia Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$177MOther investing−$149MBuybacks−$74.9MShares issued$71.9MTaxes on employees’ shares−$34.0MCash drawn (+) / kept (−)$27.0MNet borrowing (+) / repaid (−)−$14.4MOther financing−$3.7M

From profit to cash

Aurinia Pharmaceuticals: net income to operating cash flow, Q3 2026Aurinia Pharmaceuticals: net income to operating cash flow, Q3 2026Net income$31.7MDepreciation & amortization$4.8MStock-based pay$6.1MDeferred taxes$8.3MOther non-cash$584KReceivables−$6.3MInventory$1.4MPayables$1.3MAccrued liabilities$659KDeferred revenue−$503KPrepaid and other assets$2.0MOperating cash flow$46.4M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowBuybacksNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$46.4M—−$3.8M$10.4M$134M$46.4M
Q2 2026$52.6M−$38.7M−$3.4M$58.4M−$139M$52.6M
Q1 2026$32.6M−$36.2M−$3.7M$713K$39.2M$32.6M
Q4 2025$45.7M—−$3.5M$2.0M−$7.0M$45.7M
Q3 2025$44.4M−$8.7M−$3.4M$2.0M−$20.2M$44.4M
Q2 2025$44.2M−$42.6M−$6.2M$1.3M$13.4M$44.2M
Q1 2025$1.3M−$46.9M−$2.8M$9.3M$17.0M$1.3M
Q4 2024$30.1M−$21.8M−$3.0M$2.0M−$46.3M$30.1M

Aurinia Pharmaceuticals: income statement and cash flow

Aurinia Pharmaceuticals, Q3 2026: revenue $83.7M (+14% year over year), operating margin 42.3%. The chart follows the revenue to costs, profit and cash.

Aurinia Pharmaceuticals: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.